• a. Type I (Functional) nutrients and Type II (Growth) nutrients.
• b.
  • Type I (Functional nutrients): No growth retardation; specific clinical deficiency signs present (e.g. anemia, xerophthalmia); tissue concentrations decrease; body stores exist (supplementation can replenish stores). Examples: Iron, iodine, Vitamin A, Vitamin C, Vitamin D, Thiamine, Folate.
  • Type II (Growth nutrients): Causes growth faltering/stunting; no specific deficiency signs; tissue concentrations maintained; no body stores (requires daily dietary intake). Examples: Zinc, protein, potassium, sodium, magnesium, phosphorus, nitrogen, essential amino acids.
• c. Type I functional nutrients (can be stored in tissues, e.g. Vitamin A in liver, Iron in ferritin, Iodine in thyroid).
• d. Existing supplementation programs:
  • Universal: Iron and Folic Acid (Anemia Mukt Bharat), Vitamin A supplementation (bi-annual), Universal Salt Iodization.
  • Targeted: Zinc supplementation (acute diarrhea management), Vitamin K1 prophylaxis at birth, Vitamin D3 (infants), Vitamin B12 (strict vegans).

• a. Requirement: Child's age (in years) + 5 g/day (or 14 g/1,000 kcal).
• b. Types:
  • Soluble fiber: Pectins, gums, mucilages, beta-glucans.
  • Insoluble fiber: Cellulose, hemicellulose, lignin.
• c. Food items providing ~4 g of fiber per 100 g:
  • (i) Bengal gram (3.9 g / 100 g), Green gram (4.1 g / 100 g)
  • (ii) Dates (3.9 g / 100 g), Soybean (3.7 g / 100 g)
  • (iii) One medium carrot (~4 g), One medium orange (~4 g)
• d.
  • Positive effects: Increases fecal bulk, prevents constipation, increases GI transit rate, promotes colon health, serves as prebiotic producing short-chain fatty acids (SCFAs), binds bile acids to lower cholesterol, and blunts postprandial glucose spikes.
  • Negative effects: Excessive fiber (>age + 10 g) causes early satiety with reduced caloric intake, bloating/flatulence, and phytates bind divalent minerals (iron, zinc, calcium), reducing their bioavailability.

• a. Four common gut microbial phyla: Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria (and Fusobacteria).
• b.
  • Pro-inflammatory: Proteobacteria.
  • Anti-inflammatory: Firmicutes, Bacteroidetes, Actinobacteria.
• c.
  • Role in health: Fermentation of dietary fiber into SCFAs (butyrate, acetate, propionate), vitamin synthesis (Vitamin K, B complex), mucosal barrier maintenance, immune maturation, and gut-brain axis communication.
  • Role in disease: Dysbiosis is implicated in Inflammatory Bowel Disease (IBD), antibiotic-associated diarrhea, obesity, non-alcoholic fatty liver disease, asthma, allergic disorders, and autoimmune conditions.
• d. Determinants of gut microbiome: Gestational age (preterm vs term), mode of delivery (vaginal vs cesarean), feeding type (breast milk vs formula), and medications/antibiotics/dietary patterns.

• a. JUNCS:
  • J — Junk foods
  • U — Ultra-processed foods
  • N — Nutritionally inappropriate foods
  • C — Caffeinated / Carbonated / Colored foods and beverages
  • S — Sugar-sweetened beverages
• b. Junk food: Foods high in fat, salt, and sugar (HFSS) that provide empty calories with very low nutrient density (proteins, vitamins, minerals, fiber).
• c. & d. NOVA Food Classification System:
  • Group 1: Unprocessed or minimally processed foods — Natural foods altered without adding substances (e.g. fresh fruits, vegetables, whole grains, eggs, fresh milk, pasteurized milk).
  • Group 2: Processed culinary ingredients — Substances extracted directly from Group 1 foods (e.g. vegetable oils, butter, sugar, salt).
  • Group 3: Processed foods — Simple products made by adding Group 2 ingredients to Group 1 foods (e.g. canned vegetables, cheese, canned fish, fresh artisanal breads).
  • Group 4: Ultra-processed food and drink products — Industrial formulations with 5 or more ingredients including additives, emulsifiers, colorants, flavor enhancers (e.g. carbonated soft drinks, sweet/savory packaged snacks, chocolates, candies, chicken nuggets, instant noodles).

• a. Mechanism: Folate acts as a methyl group donor in one-carbon metabolism, enabling epigenetic DNA methylation that regulates expression of critical genes involved in neural tube closure and embryonic development.
• b. Preventable birth defects: Neural tube defects (anencephaly, spina bifida, encephalocele), conotruncal cardiac anomalies, and cleft lip/palate.
• c.
  • Period: Periconceptional period—at least 1 month before conception and continued through the first 12 weeks of pregnancy.
  • Dose:
    • Universal / Low risk: 400 µg (0.4 mg) daily.
    • High risk (prior affected child, maternal antiepileptic therapy, pregestational diabetes, maternal obesity): 4–5 mg daily.
• d. Folate trap / Side effect: Excess folate supplementation can correct the megaloblastic anemia of Vitamin B12 deficiency while allowing irreversible subacute combined degeneration of the spinal cord (SCD) to progress unnoticed.

• a. Reductive adaptation: Downregulation of energy-consuming metabolic pathways and organ function to ensure survival in the presence of severe nutrient restriction.
• b. Five key adaptations:
  1. Decreased physical activity and growth cessation.
  2. Reduction in basal metabolic rate by slowing cellular protein turnover.
  3. Decreased functional reserve of vital organs (cardiac output, renal GFR, liver synthetic function).
  4. Downregulation of membrane Na+/K+ ATPase pumps, leading to cellular sodium retention and potassium loss.
  5. Suppression of cell-mediated immunity and inflammatory cascades.
• c. Nutritionally Acquired Immune Deficiency Syndrome (NAIDS).
• d. Difference from HIV-AIDS: NAIDS is characterized by hypogammaglobulinemia (or defective antibody response with normal total Ig), absence of generalized lymphadenopathy, absence of retroviral serology, and complete reversibility with nutritional rehabilitation.

• a. Refeeding syndrome.
• b. Pathophysiology:
  • High-energy/high-carbohydrate refeeding triggers insulin secretion.
  • Insulin promotes rapid cellular uptake of glucose, phosphate, potassium, and magnesium.
  • This leads to acute profound hypophosphatemia, hypokalemia, and hypomagnesemia.
  • Concurrently, sodium and water retention occur due to increased sodium pump activity, leading to extracellular fluid expansion and congestive cardiac failure.
• c. Complications:
  • Severe hypophosphatemia (cardiac failure, arrhythmias, respiratory failure, rhabdomyolysis, seizures, coma, death).
  • Hypokalemic arrhythmias and paralytic ileus.
  • Acute pulmonary edema and fluid overload.
  • Thiamine deficiency encephalopathy (Wernicke encephalopathy / lactic acidosis).
• d. Management:
  • Cautious starter feeding (F-75: 80–100 kcal/kg/day; protein 1–1.5 g/kg/day); avoid rapid escalation to F-100 or catch-up formulas.
  • Monitor electrolytes (phosphate, potassium, magnesium) and blood glucose.
  • Correct electrolyte deficits promptly with potassium, magnesium, and phosphate.
  • Administer Thiamine (50–100 mg IV/oral) prior to feeding.
  • Fluid restriction and close cardiorespiratory monitoring.

• a. Signs of fluid overload in SAM:
  • Increase in respiratory rate by ≥5 breaths/minute.
  • Development of grunting respiration or chest indrawing.
  • Appearance of bilateral basal fine crepitations/crackles in lungs.
  • Increase in heart rate by ≥15 beats/minute.
  • Development of gallop rhythm (S3).
  • Rapid increase in liver size (>2 cm enlargement).
• b. Treatment of dehydration with shock in SAM:
  • Administer IV fluids only if lethargic/unconscious AND features of shock (cold peripheries, capillary refill time >3 sec, weak/thready pulse).
  • Fluid: Ringer's Lactate in 5% Dextrose OR Half-strength Darrow's in 5% Dextrose OR 0.45% Saline in 5% Dextrose at 15 mL/kg over 1 hour.
  • Monitor pulse, respiration, and liver size every 5–10 minutes.
  • If improved: Give 10 mL/kg/h for up to 2 hours, then switch to oral/NG ReSoMal (5–10 mL/kg/h).
  • If no improvement or signs of fluid overload develop: Stop IV infusion, consider septic/cardiogenic shock, start IV broad-spectrum antibiotics and inotropic support (dopamine/epinephrine).

• a. ReSoMal: Rehydration Solution for Malnourished children.
• b. Composition Comparison:

Constituent	WHO Reduced Osmolarity ORS	ReSoMal	Modified ORS
Glucose (g/L)	13.5 (75 mmol/L)	35 (125 mmol/L)	32 (122 mmol/L)
Sodium (mEq/L)	75	45	38
Potassium (mEq/L)	20	40	40
Chloride (mEq/L)	65	70	70
Citrate (mEq/L)	10	7	5
Magnesium (mEq/L)	—	3	—
Zinc (mEq/L)	—	0.3	—
Copper (mEq/L)	—	0.045	—
Total Osmolarity (mOsm/L)	245	300	300

Rationale: Children with SAM have high intracellular sodium (impaired Na+/K+ ATPase) and severe total-body potassium/magnesium depletion. ReSoMal provides less sodium (to prevent fluid overload/heart failure) and more potassium & glucose.

• c. Bedside Preparation of Modified ORS / ReSoMal:
  • Step 1: Dissolve one standard 1-liter sachet of WHO-ORS in 2 liters of clean boiled and cooled water.
  • Step 2: Add 50 g of sucrose (sugar) (approx. 10 level teaspoons).
  • Step 3: Add 45 mL of Syrup Potclor (Potassium Chloride, ~60 mEq K+) OR 30 mL of 15% IV KCl solution.

• a. Celiac Disease (Gluten-sensitive enteropathy).
• b. Initial Approach:
  • Quantitative serum total IgA level with anti-tissue transglutaminase (anti-tTG) IgA antibody.
  • If anti-tTG is positive: Confirm with upper GI endoscopy and multiple duodenal biopsies demonstrating villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis (Marsh classification).
• c. Gluten-Free Foods to Include (Inclusion list): Rice, maize/corn, sorghum (jowar), pearl millet (bajra), finger millet (ragi), pulses and legumes, soybean, potatoes, tapioca, fresh fruits, vegetables, milk, eggs, and meat.
• d. Gluten-Containing Foods to Exclude (Exclusion list): Wheat (gehun), barley (jau), rye, semolina (suji/rava), refined flour (maida), commercial breads, pastries, pasta, noodles, biscuits, and malt-containing drinks.

• a. Cystic Fibrosis (CF).
• b. Confirmation:
  • Sweat chloride test: Quantitative pilocarpine iontophoresis demonstrating sweat chloride ≥60 mmol/L on two occasions.
  • Genetic testing demonstrating 2 disease-causing CFTR mutations.
• c. Pancreatic Enzyme Replacement Therapy (PERT):
  • Enteric-coated microtablets/minimicrospheres administered with every meal and snack.
  • Starting dose:
    • Infants: 2,000–4,000 lipase units per 120 mL of milk/formula (or 450–900 units/g fat).
    • Children <4 years: 1,000 lipase units/kg/meal; 500 units/kg/snack.
    • Children >4 years: 500 lipase units/kg/meal; 250 units/kg/snack.
• d. Titration:
  • Titrate according to stool consistency, steatorrhea, and weight gain velocity.
  • Maximum recommended dose: <2,500 lipase units/kg/meal or <10,000 lipase units/kg/day (excessive dosing is associated with fibrosing colonopathy).

• a. Food Allergy (IgE-mediated food allergy / acute urticaria-angioedema).
• b. Pathogenetic factors:
  1. Genetic predisposition / Atopic family history.
  2. Immaturity/defects in the gut mucosal barrier ("leaky gut").
  3. Aberrant Th2 immune sensitization with specific IgE production.
• c. Common food allergens: Cow's milk protein, hen's egg, peanuts, tree nuts, soybean, wheat, fish, and shellfish/shrimp.
• d. Preventive strategies:
  1. Exclusive breastfeeding for the first 6 months of life.
  2. Early introduction of complementary foods including potential allergens (peanut/egg) between 6–12 months rather than delaying them.
  3. No maternal dietary restrictions during pregnancy and lactation.

• a. Definitions (IAP 2015 BMI charts for Indian children 5–18 years):
  • Overweight: BMI ≥ 23rd adult equivalent cut-off (≥75th percentile).
  • Obesity: BMI ≥ 27th adult equivalent cut-off (≥95th percentile).
• b. Metabolic syndrome (along with non-alcoholic fatty liver disease [NAFLD], hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea, and slipped capital femoral epiphysis).
• c. IDF Criteria for Metabolic Syndrome (10–16 years):
  • Abdominal obesity: Waist circumference ≥90th percentile for age/sex PLUS any 2 of the following:
    1. Fasting triglycerides ≥150 mg/dL.
    2. HDL-cholesterol <40 mg/dL.
    3. Blood pressure: Systolic BP ≥130 mm Hg or Diastolic BP ≥85 mm Hg (or ≥95th percentile).
    4. Fasting blood glucose ≥100 mg/dL (or diagnosed T2DM).
• d. Diet and Lifestyle Modification:
  • Follow the 5-2-1-0 rule:
    • 5 or more servings of fruits and vegetables daily.
    • 2 hours or less of recreational screen time daily.
    • 1 hour or more of moderate-to-vigorous physical activity daily.
    • 0 sugar-sweetened beverages; promote plain water.
  • Implement the "Traffic Light Diet" (green: eat freely; yellow: caution/moderation; red: avoid/restrict).

• a. Pathological Bowlegs (Genu Varum):
  • Persistence or progression beyond 2 years of age.
  • Intercondylar distance (ICD) >6 cm with medial malleoli touching.
  • Unilateral or asymmetric bowing.
  • Associated short stature (<3rd percentile) or signs of rickets (wrist widening, rachitic rosary).
• b. Probable diagnosis & investigations:
  • Diagnosis: Nutritional Vitamin D deficiency rickets (or Blount disease, hypophosphatemic rickets, renal osteodystrophy).
  • Investigations: Serum Calcium (low/normal), Phosphorus (low), Alkaline Phosphatase (markedly elevated), 25-OH Vitamin D (low), Serum PTH (elevated), and X-rays of wrists/knees (metaphyseal cupping, fraying, splaying).
• c. 25-OH Vitamin D Levels:
  • Deficiency: <12 ng/mL (<30 nmol/L)
  • Insufficiency: 12–20 ng/mL (30–50 nmol/L)
  • Sufficiency: >20 ng/mL (>50 nmol/L)
• d. Management:

Age Group	Daily Stoss Regimen (for 12 weeks)	Alternative Intermittent Regimen	Maintenance Daily Dose
<6 months	2,000 IU/day	Not recommended	400 IU/day
6–12 months	2,000 IU/day	60,000 IU once a month for 3 months	400 IU/day
>12 months	3,000–6,000 IU/day	60,000 IU once weekly for 6 weeks (or every 2 weeks × 5 doses)	600 IU/day

Calcium supplementation: Provide elemental calcium at 50–75 mg/kg/day in 2–3 divided doses to prevent hungry bone syndrome.

• a. Ketogenic Diet (KD): A high-fat, low-carbohydrate, adequate-protein dietary regimen (classic 4:1 or 3:1 lipid to non-lipid ratio by weight).
• b. Mechanism: Ketogenic diet forces cellular energy metabolism away from glucose towards ketone bodies (β-hydroxybutyrate, acetoacetate) synthesized from hepatic fatty acid oxidation. Ketone bodies increase GABA synthesis, decrease neuronal excitability, enhance mitochondrial biogenesis, and open ATP-sensitive potassium channels.
• c. Conditions indicated:
  • Glucose Transporter 1 (GLUT-1) Deficiency Syndrome (treatment of choice)
  • Pyruvate Dehydrogenase Deficiency (PDHD)
  • Dravet syndrome, Lennox-Gastaut syndrome, infantile spasms (West syndrome), and Tuberous Sclerosis Complex.
• d. Vitamin-responsive epilepsies:
  1. Pyridoxine (Vitamin B6) / Pyridoxal-5-Phosphate responsive epilepsy: Antiquitin (ALDH7A1) deficiency / PNPO deficiency.
  2. Biotin-responsive seizures: Biotinidase deficiency / Holocarboxylase synthetase deficiency.
  3. Biotin-Thiamine-Responsive Basal Ganglia Disease (BTBGD): SLC19A3 mutation.
  4. Folate-responsive seizures: Cerebral folate deficiency (FOLR1 mutation).